These findings highlight a novel physiological role of ERRα contributing for the sex disparity in VLDL secretion, providing an insight that a therapeutic approach for fatty liver involved selectively restoring hepatic ERRα activity, especially suitable for postmenopausal women with early stage NAFLD. Here, ESRRA is linked to metabolic dysfunction-associated steatotic liver disease.